Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.

Sphingosine 1-phosphate (S1P) is the endogenous ligand for the sphingosine 1-phosphate receptors (S1P1-5) and evokes a variety of cellular responses through their stimulation. The interaction of S1P with the S1P receptors plays a fundamental physiological role in a number of processes including vascular development and stabilization, lymphocyte migration, and proliferation. Agonism of S1P1, in particular, has been shown to play a significant role in lymphocyte trafficking from the thymus and secondary lymphoid organs, resulting in immunosuppression. This article will detail the discovery and SAR of a potent and selective series of isoxazole based full agonists of S1P1. Isoxazole 6d demonstrated impressive efficacy when administered orally in a rat model of arthritis and in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis.

[1]  S. H. Kim,et al.  Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor. , 2015, Bioorganic & medicinal chemistry letters.

[2]  I. Wall,et al.  Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles. , 2014, Journal of medicinal chemistry.

[3]  A. Blackburn,et al.  (7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists. , 2014, ACS medicinal chemistry letters.

[4]  E. Hickey,et al.  Piperazinyl-oxadiazoles as selective sphingosine-1-phosphate receptor agonists. , 2014, Bioorganic & medicinal chemistry letters.

[5]  Xiaojian Wang,et al.  Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design. , 2014, European journal of medicinal chemistry.

[6]  R. de Kanter,et al.  Novel S1P(1) receptor agonists--part 3: from thiophenes to pyridines. , 2014, Journal of medicinal chemistry.

[7]  R. de Kanter,et al.  Novel S1P(1) receptor agonists--part 2: from bicyclo[3.1.0]hexane-fused thiophenes to isobutyl substituted thiophenes. , 2014, Journal of medicinal chemistry.

[8]  N. Gray,et al.  The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate , 2012, British journal of pharmacology.

[9]  D. Hafler,et al.  Fingolimod for multiple sclerosis. , 2012, The New England journal of medicine.

[10]  A. Dyckman.  Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists , 2012 .

[11]  J. Chun,et al.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). , 2011, Discovery medicine.

[12]  Volker Brinkmann,et al.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis , 2010, Nature Reviews Drug Discovery.

[13]  H. Hartung,et al.  Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis , 2010, Clinical neuropharmacology.

[14]  T. Hla,et al.  The vascular S1P gradient-cellular sources and biological significance. , 2008, Biochimica et biophysica acta.

[15]  J. Cyster,et al.  S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. , 2008, Immunity.

[16]  J. Cyster,et al.  Finding a way out: lymphocyte egress from lymphoid organs , 2007, Nature Immunology.

[17]  J. Cyster,et al.  Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate , 2007, Science.

[18]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[19]  S. A. Parent,et al.  Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3. , 2005, Journal of medicinal chemistry.

[20]  E. Goetzl,et al.  Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network , 2005, Nature Reviews Immunology.

[21]  M. Ferrer,et al.  A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists. , 2004, Journal of medicinal chemistry.

[22]  R. Proia,et al.  Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[23]  R. Proia,et al.  Expression of the Sphingosine 1-Phosphate Receptor, S1P1, on T-cells Controls Thymic Emigration* , 2004, Journal of Biological Chemistry.

[24]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[25]  F. Qing,et al.  Asymmetric synthesis of both enantiomers of anti-4,4,4-trifluorothreonine and 2-amino-4,4,4-trifluorobutanoic acid. , 2003, The Journal of organic chemistry.

[26]  B. Hamper,et al.  Reaction of benzohydroximinoyl chlorides and β-(trifluoromethyl)-acetylenic esters: Synthesis of regioisomeric (trifluoromethyl)-isoxazolecarboxylate esters and oxime addition products , 2003 .

[27]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[28]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[29]  A. Bendele,et al.  Animal Models of Arthritis: Relevance to Human Disease , 1999, Toxicologic pathology.

[30]  L. K.‐C.,et al.  ベンゾヒドロキシイミノイルクロリド(ニトリルオキシド前駆体)の非常に便利な製造 , 1980 .